Pharmacology Quiz: Pk Vs Pd Interactions
20 questions · exam conditions
0:00
Pk Vs Pd InteractionsQuestion 1 of 20

A patient who chronically consumes large amounts of alcohol is given a standard intravenous dose of diazepam for procedural sedation. The patient experiences profound and prolonged respiratory depression, far greater than anticipated.

Which combination of interactions best explains this exaggerated response?

Pharmacodynamic antagonism at the GABA-A receptor, combined with pharmacokinetic induction of diazepam metabolism from chronic alcohol use.
A purely pharmacokinetic interaction where acute alcohol intake blocks the renal excretion of diazepam and its active metabolites.
Pharmacodynamic synergism at the GABA-A receptor, combined with a pharmacokinetic interaction where acute alcohol intake inhibits diazepam metabolism.
A purely pharmacodynamic interaction where both agents non-competitively inhibit CNS neurotransmission through separate, unrelated pathways.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Pk Vs Pd Interactions

Practice Pk Vs Pd Interactions in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Pk Vs Pd Interactions, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient who chronically consumes large amounts of alcohol is given a standard intravenous dose of diazepam for procedural sedation. The patient experiences profound and prolonged respiratory depression, far greater than anticipated.

Which combination of interactions best explains this exaggerated response?

  1. Pharmacodynamic antagonism at the GABA-A receptor, combined with pharmacokinetic induction of diazepam metabolism from chronic alcohol use.
  2. A purely pharmacokinetic interaction where acute alcohol intake blocks the renal excretion of diazepam and its active metabolites.
  3. Pharmacodynamic synergism at the GABA-A receptor, combined with a pharmacokinetic interaction where acute alcohol intake inhibits diazepam metabolism. (correct answer)
  4. A purely pharmacodynamic interaction where both agents non-competitively inhibit CNS neurotransmission through separate, unrelated pathways.
Explanation: The correct answer acknowledges both a key pharmacodynamic and a key pharmacokinetic interaction. Pharmacodynamically, both ethanol and benzodiazepines like diazepam are positive allosteric modulators of the GABA-A receptor, the primary inhibitory neurotransmitter receptor in the CNS. Their combined action leads to synergistic CNS depression. Pharmacokinetically, while chronic alcohol use induces CYP enzymes, acute high-dose alcohol consumption can competitively inhibit CYP enzymes (like CYP3A4 and 2C19) that metabolize diazepam, slowing its clearance and prolonging its effects. The combination of these two mechanisms explains the profound sedation. A is incorrect; the interaction is synergistic, not antagonistic, and while chronic induction is a factor, acute inhibition is more relevant to this scenario. B is incorrect; diazepam is cleared by hepatic metabolism, not primarily renal excretion. D is incorrect because the interaction is not purely pharmacodynamic, and the agents act on the same receptor complex, not unrelated pathways.

Question 2

A patient taking warfarin for atrial fibrillation is advised to start low-dose aspirin after a transient ischemic attack. The patient's physician counsels them about an increased risk of bleeding.

Which of the following best describes the primary mechanism for the increased bleeding risk with this combination?

  1. An additive pharmacokinetic interaction, as aspirin inhibits the CYP2C9-mediated metabolism of warfarin, increasing its concentration.
  2. A synergistic pharmacodynamic interaction, as both drugs impair hemostasis through independent mechanisms (anticoagulation and anti-platelet effects). (correct answer)
  3. An antagonistic pharmacokinetic interaction, as aspirin displaces warfarin from albumin, leading to a transient increase in effect followed by faster clearance.
  4. A synergistic pharmacokinetic interaction, as both drugs compete for the same renal excretion pathway, increasing the half-life of both agents.
Explanation: The correct answer identifies the primary pharmacodynamic interaction. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors, impairing the coagulation cascade. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, preventing the formation of thromboxane A2 and thus inhibiting platelet aggregation. Because these drugs disrupt two different and crucial components of hemostasis (clotting factors and platelets), their combined effect on bleeding risk is synergistic (greater than the sum of their individual effects). A is incorrect; while high-dose salicylates can inhibit warfarin metabolism, this is not the primary mechanism, especially with low-dose aspirin. C describes protein binding displacement, which is a minor and transient effect compared to the major PD interaction. D describes an incorrect pharmacokinetic mechanism.

Question 3

A renal transplant recipient is stable on a maintenance dose of tacrolimus, an immunosuppressant. They begin self-medicating with St. John's Wort for mild depression. A routine blood test reveals that their tacrolimus trough levels are dangerously low, placing them at high risk for organ rejection.

The observed change in tacrolimus levels is best explained by:

  1. A pharmacokinetic interaction where St. John's Wort, a potent inducer of CYP3A4 and P-glycoprotein, has increased the clearance of tacrolimus. (correct answer)
  2. A pharmacokinetic interaction where St. John's Wort inhibits CYP3A4 and P-glycoprotein, paradoxically leading to increased clearance.
  3. A pharmacodynamic interaction where St. John's Wort has a pro-inflammatory effect that counteracts the immunosuppressive action of tacrolimus.
  4. A pharmacokinetic interaction where St. John's Wort enhances the glomerular filtration of tacrolimus without affecting its metabolism.
Explanation: The correct answer identifies a well-documented pharmacokinetic interaction. Tacrolimus is a substrate of both the metabolic enzyme CYP3A4 and the efflux transporter P-glycoprotein, both of which are highly expressed in the gut and liver. St. John's Wort is a potent inducer of both CYP3A4 and P-glycoprotein. By inducing these systems, St. John's Wort significantly increases both the first-pass and systemic metabolism and clearance of tacrolimus, leading to subtherapeutic blood levels and the risk of allograft rejection. B incorrectly states that St. John's Wort is an inhibitor. C describes a pharmacodynamic mechanism, but the observed change in drug levels clearly points to a pharmacokinetic interaction. D describes an incorrect pharmacokinetic mechanism; the effect is on metabolism and transport, not glomerular filtration.

Question 4

A patient with a mechanical heart valve has a stable international normalized ratio (INR) of 2.8 on a consistent dose of warfarin. After being diagnosed with tuberculosis, the patient begins a multi-drug regimen that includes rifampin. Two weeks later, their INR is found to be 1.2.

Which statement best describes the interaction responsible for the change in INR?

  1. A pharmacodynamic interaction where rifampin enhances the synthesis of vitamin K-dependent clotting factors, directly opposing warfarin's effect.
  2. A pharmacokinetic interaction where rifampin displaces warfarin from albumin, leading to an initial increase in free drug followed by more rapid clearance.
  3. A pharmacokinetic interaction where rifampin, a potent enzyme inducer, significantly increases the metabolic clearance of warfarin via CYP2C9. (correct answer)
  4. A pharmacokinetic interaction where rifampin chelates warfarin in the gastrointestinal tract, thereby reducing its oral bioavailability.
Explanation: The correct answer identifies the well-established pharmacokinetic interaction between rifampin and warfarin. Rifampin is one of the most potent inducers of cytochrome P450 enzymes, including CYP2C9 which is the primary enzyme responsible for metabolizing the more potent S-enantiomer of warfarin. Induction of CYP2C9 leads to a greatly accelerated rate of warfarin metabolism, a lower plasma concentration, and a subtherapeutic INR, increasing the risk of thrombosis. A describes a plausible but incorrect pharmacodynamic mechanism. Rifampin does not directly affect clotting factor synthesis. B describes protein displacement, which is another type of pharmacokinetic interaction. However, the primary and most clinically significant interaction with rifampin is potent enzyme induction, not protein displacement. D describes an absorption interaction (chelation), which is not the mechanism for the rifampin-warfarin interaction.

Question 5

A patient is prescribed ciprofloxacin for a urinary tract infection. The patient also takes a daily calcium carbonate supplement for osteoporosis. If both are taken simultaneously by mouth, which statement best describes the resulting interaction?

  1. A pharmacodynamic interaction occurs where calcium ions interfere with the binding of ciprofloxacin to bacterial DNA gyrase, antagonizing its effect.
  2. A pharmacokinetic interaction occurs where calcium carbonate increases gastric pH, which chemically degrades the acid-labile ciprofloxacin before it can be absorbed.
  3. A pharmacokinetic interaction occurs in the GI tract where polyvalent cations from the supplement form an insoluble chelate with ciprofloxacin, reducing its absorption. (correct answer)
  4. A pharmacokinetic interaction occurs where ciprofloxacin inhibits the renal excretion of calcium, leading to a dangerous risk of hypercalcemia.
Explanation: The correct answer describes a classic pharmacokinetic interaction based on chelation. Fluoroquinolones, like ciprofloxacin, and tetracyclines can bind with polyvalent cations (e.g., Ca2+, Mg2+, Al3+, Fe2+) in the gastrointestinal tract to form insoluble chelate complexes. This process prevents the antibiotic from being absorbed into the systemic circulation, leading to subtherapeutic drug levels and potential treatment failure. For this reason, administration should be separated by several hours. A is incorrect; the interaction is pharmacokinetic (absorption), not pharmacodynamic (at the bacterial target). B describes a plausible mechanism for other drugs (like some proton pump inhibitors), but fluoroquinolones are not particularly acid-labile. D describes an incorrect pharmacokinetic mechanism and consequence.

Question 6

A patient being treated with isosorbide mononitrate for stable angina is prescribed sildenafil for erectile dysfunction. Concomitant use of these two agents is strictly contraindicated due to the risk of a severe, life-threatening reaction.

What is the fundamental mechanism of this critical drug interaction?

  1. A pharmacokinetic interaction where sildenafil potently inhibits the hepatic metabolism of isosorbide mononitrate, leading to dangerously high nitrate levels.
  2. A pharmacodynamic interaction where both drugs act as competitive agonists at the same vascular smooth muscle receptor, causing overstimulation.
  3. A pharmacokinetic interaction where isosorbide mononitrate alters gastric pH, dramatically increasing the oral bioavailability of sildenafil.
  4. A pharmacodynamic interaction where nitrates and sildenafil act on different steps of the cGMP pathway, leading to a synergistic and profound vasodilation. (correct answer)
Explanation: The correct answer describes a classic and dangerous pharmacodynamic interaction. Both drugs cause vasodilation via the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway. Nitrates (like isosorbide mononitrate) increase the synthesis of cGMP by activating guanylate cyclase. Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor, which prevents the breakdown of cGMP. The combined effect is a synergistic and massive accumulation of cGMP, leading to profound vasodilation, severe hypotension, and potentially fatal cardiovascular collapse. A is incorrect; the mechanism is pharmacodynamic, not pharmacokinetic. B describes an incorrect pharmacodynamic mechanism; the drugs do not act on the same receptor, but on different enzymes in the same signaling pathway. C describes an incorrect pharmacokinetic mechanism.

Question 7

A 68-year-old patient with well-controlled hypertension on lisinopril develops osteoarthritis and begins taking naproxen 500 mg twice daily. During a follow-up visit, their blood pressure, previously at goal, is significantly elevated.

This change in blood pressure is most likely due to which type of interaction?

  1. A pharmacokinetic interaction in which naproxen induces the renal clearance of lisinopril, reducing its plasma concentration.
  2. A pharmacodynamic interaction in which naproxen inhibits prostaglandin synthesis, leading to afferent arteriole vasoconstriction and sodium retention. (correct answer)
  3. A pharmacodynamic interaction in which naproxen directly antagonizes angiotensin II receptors, competing with the effects of lisinopril.
  4. A pharmacokinetic interaction in which naproxen displaces lisinopril from plasma proteins, reducing its therapeutic effect at the target site.
Explanation: The correct answer describes a physiological antagonism, which is a type of pharmacodynamic interaction. NSAIDs like naproxen inhibit cyclooxygenase (COX) enzymes, reducing the synthesis of renal vasodilating prostaglandins. This leads to vasoconstriction of the afferent arteriole of the glomerulus and increased renal sodium and water retention. Both effects counteract the blood pressure-lowering effects of ACE inhibitors like lisinopril. A is incorrect because this is not a known pharmacokinetic interaction; the mechanism is pharmacodynamic. C describes an incorrect pharmacodynamic mechanism. Naproxen does not interact with angiotensin II receptors. D describes an incorrect pharmacokinetic mechanism. Lisinopril is not significantly protein-bound, so displacement is not a relevant mechanism.

Question 8

A patient is prescribed sertraline for depression. Several weeks later, they are inadvertently prescribed phenelzine, a monoamine oxidase inhibitor (MAOI), by a different provider. The patient presents to the emergency department with autonomic instability, altered mental status, and neuromuscular hyperactivity.

This clinical scenario is a classic example of which type of interaction?

  1. A pharmacokinetic interaction where phenelzine inhibits the CYP enzymes responsible for sertraline metabolism, causing toxic accumulation.
  2. A pharmacodynamic interaction resulting in a synergistic increase in synaptic serotonin levels, leading to serotonin syndrome. (correct answer)
  3. A pharmacokinetic interaction where sertraline displaces phenelzine from plasma proteins, increasing its free concentration and toxicity.
  4. A pharmacodynamic interaction where sertraline and phenelzine competitively bind to the same monoamine oxidase enzyme.
Explanation: The correct answer describes the pharmacodynamic basis of serotonin syndrome. Sertraline is a selective serotonin reuptake inhibitor (SSRI), which increases synaptic serotonin by blocking its reabsorption. Phenelzine is a monoamine oxidase inhibitor (MAOI), which increases synaptic serotonin by preventing its breakdown. When used together, these two distinct mechanisms produce a synergistic and dangerous elevation of serotonin levels, leading to the clinical toxidrome of serotonin syndrome. A is incorrect. While MAOIs can inhibit some CYP enzymes, the primary mechanism of this life-threatening interaction is pharmacodynamic, not pharmacokinetic. C describes an incorrect pharmacokinetic mechanism. D describes an incorrect pharmacodynamic mechanism; sertraline does not bind to the MAO enzyme.

Question 9

A patient taking fluoxetine for major depressive disorder requires analgesia after a dental procedure and is prescribed a combination product containing codeine. The patient reports minimal pain relief despite taking the medication as directed.

The lack of analgesic efficacy is most likely due to which type of drug interaction?

  1. A pharmacodynamic interaction where fluoxetine antagonizes mu-opioid receptors in the central nervous system, blocking the effects of codeine.
  2. A pharmacokinetic interaction where fluoxetine induces the rapid metabolism of codeine into inactive metabolites, reducing its effective half-life.
  3. A pharmacodynamic interaction where elevated serotonin levels from fluoxetine alter pain perception pathways, rendering opioid analgesics ineffective.
  4. A pharmacokinetic interaction where fluoxetine, a potent CYP2D6 inhibitor, prevents the metabolic conversion of codeine to its active metabolite, morphine. (correct answer)
Explanation: The correct answer describes the pharmacokinetic basis for this interaction. Codeine is a prodrug that exerts most of its analgesic effect after being metabolized into morphine. This conversion is primarily carried out by the CYP2D6 enzyme. Fluoxetine (and its active metabolite, norfluoxetine) is a potent inhibitor of CYP2D6. By inhibiting the enzyme, fluoxetine blocks the activation of codeine, leading to low morphine levels and a lack of analgesic effect. A is incorrect; the mechanism is PK, not PD. Fluoxetine does not block opioid receptors. B is incorrect as fluoxetine is an inhibitor, not an inducer, of CYP2D6. C describes a plausible-sounding but incorrect PD mechanism. The primary interaction is the well-documented PK effect on codeine's activation.

Question 10

A patient with coronary artery disease, stable on clopidogrel therapy, is prescribed omeprazole for gastroesophageal reflux disease. Several weeks later, the patient is hospitalized for an acute stent thrombosis.

What is the most likely mechanism underlying this adverse clinical event?

  1. A pharmacodynamic interaction where omeprazole directly antagonizes the P2Y12 receptor, negating the effect of clopidogrel.
  2. A pharmacokinetic interaction where omeprazole induces the hepatic metabolism of clopidogrel's active metabolite, reducing its half-life.
  3. A pharmacokinetic interaction where omeprazole inhibits the CYP2C19 enzyme, preventing the metabolic activation of the prodrug clopidogrel. (correct answer)
  4. A pharmacodynamic interaction where omeprazole-induced elevation in gastric pH leads to a systemic pro-thrombotic state.
Explanation: The correct answer describes a critical pharmacokinetic interaction. Clopidogrel is a prodrug that requires bioactivation to its active metabolite by the cytochrome P450 enzyme CYP2C19. Omeprazole is a known inhibitor of CYP2C19. By inhibiting this enzyme, omeprazole reduces the formation of the active clopidogrel metabolite, leading to diminished antiplatelet effect and an increased risk of thrombotic events. A is incorrect because the interaction is pharmacokinetic (affecting metabolism), not pharmacodynamic (affecting the receptor site). Omeprazole does not bind to the P2Y12 receptor. B is incorrect because omeprazole is an inhibitor, not an inducer, of the relevant enzyme. Induction would cause faster metabolism, but inhibition causes slower metabolism/activation. D describes an incorrect pharmacodynamic mechanism; while pH changes can affect drug absorption, they do not cause a pro-thrombotic state in this manner.

Question 11

A patient with hyperlipidemia is well-controlled on simvastatin 40 mg daily. Seeking to improve their diet, they begin drinking one liter of grapefruit juice each day. Two weeks later, they contact their physician complaining of significant muscle aches.

Which statement most accurately describes the interaction responsible for the patient's symptoms?

  1. A pharmacokinetic interaction occurred, as grapefruit juice induced intestinal CYP3A4, leading to decreased simvastatin levels and a return of hyperlipidemia.
  2. A pharmacodynamic interaction occurred, where components in grapefruit juice directly activate HMG-CoA reductase, antagonizing the therapeutic effect of simvastatin.
  3. A pharmacokinetic interaction occurred, as components in grapefruit juice irreversibly inhibit intestinal CYP3A4, increasing simvastatin bioavailability. (correct answer)
  4. No significant interaction is expected, as the effects of grapefruit juice on drug metabolism are only relevant for intravenous, not oral, medications.
Explanation: The correct answer describes the classic interaction between grapefruit juice and CYP3A4 substrates. Simvastatin undergoes extensive first-pass metabolism in the intestinal wall by CYP3A4. Furanocoumarins in grapefruit juice are mechanism-based (suicide) inhibitors of intestinal CYP3A4, meaning they irreversibly inactivate the enzyme. This dramatically reduces first-pass metabolism, leading to a several-fold increase in the oral bioavailability and systemic exposure to simvastatin, which increases the risk of concentration-dependent adverse effects like myopathy. A incorrectly states that grapefruit juice is an inducer; it is a potent inhibitor. B describes an incorrect pharmacodynamic mechanism. D is incorrect; this interaction is most significant for orally administered drugs that have high first-pass metabolism via CYP3A4.

Question 12

A patient with coronary artery disease, stable on clopidogrel therapy, is prescribed omeprazole for gastroesophageal reflux disease. Several weeks later, the patient is hospitalized for an acute stent thrombosis.

What is the most likely mechanism underlying this adverse clinical event?

  1. A pharmacodynamic interaction where omeprazole directly antagonizes the P2Y12 receptor, negating the effect of clopidogrel.
  2. A pharmacokinetic interaction where omeprazole induces the hepatic metabolism of clopidogrel's active metabolite, reducing its half-life.
  3. A pharmacokinetic interaction where omeprazole inhibits the CYP2C19 enzyme, preventing the metabolic activation of the prodrug clopidogrel. (correct answer)
  4. A pharmacodynamic interaction where omeprazole-induced elevation in gastric pH leads to a systemic pro-thrombotic state.
Explanation: The correct answer describes a critical pharmacokinetic interaction. Clopidogrel is a prodrug that requires bioactivation to its active metabolite by the cytochrome P450 enzyme CYP2C19. Omeprazole is a known inhibitor of CYP2C19. By inhibiting this enzyme, omeprazole reduces the formation of the active clopidogrel metabolite, leading to diminished antiplatelet effect and an increased risk of thrombotic events. A is incorrect because the interaction is pharmacokinetic (affecting metabolism), not pharmacodynamic (affecting the receptor site). Omeprazole does not bind to the P2Y12 receptor. B is incorrect because omeprazole is an inhibitor, not an inducer, of the relevant enzyme. Induction would cause faster metabolism, but inhibition causes slower metabolism/activation. D describes an incorrect pharmacodynamic mechanism; while pH changes can affect drug absorption, they do not cause a pro-thrombotic state in this manner.

Question 13

A patient with a mechanical heart valve has a stable international normalized ratio (INR) of 2.8 on a consistent dose of warfarin. After being diagnosed with tuberculosis, the patient begins a multi-drug regimen that includes rifampin. Two weeks later, their INR is found to be 1.2.

Which statement best describes the interaction responsible for the change in INR?

  1. A pharmacodynamic interaction where rifampin enhances the synthesis of vitamin K-dependent clotting factors, directly opposing warfarin's effect.
  2. A pharmacokinetic interaction where rifampin displaces warfarin from albumin, leading to an initial increase in free drug followed by more rapid clearance.
  3. A pharmacokinetic interaction where rifampin, a potent enzyme inducer, significantly increases the metabolic clearance of warfarin via CYP2C9. (correct answer)
  4. A pharmacokinetic interaction where rifampin chelates warfarin in the gastrointestinal tract, thereby reducing its oral bioavailability.
Explanation: The correct answer identifies the well-established pharmacokinetic interaction between rifampin and warfarin. Rifampin is one of the most potent inducers of cytochrome P450 enzymes, including CYP2C9 which is the primary enzyme responsible for metabolizing the more potent S-enantiomer of warfarin. Induction of CYP2C9 leads to a greatly accelerated rate of warfarin metabolism, a lower plasma concentration, and a subtherapeutic INR, increasing the risk of thrombosis. A describes a plausible but incorrect pharmacodynamic mechanism. Rifampin does not directly affect clotting factor synthesis. B describes protein displacement, which is another type of pharmacokinetic interaction. However, the primary and most clinically significant interaction with rifampin is potent enzyme induction, not protein displacement. D describes an absorption interaction (chelation), which is not the mechanism for the rifampin-warfarin interaction.

Question 14

A patient with bipolar disorder, well-maintained on a stable dose of lithium, is started on hydrochlorothiazide for newly diagnosed hypertension. Three weeks later, the patient presents with coarse tremor, confusion, and ataxia. Serum lithium levels are found to be in the toxic range.

This adverse event is the result of which of the following mechanisms?

  1. A pharmacodynamic interaction where hydrochlorothiazide alters neuronal ion channel sensitivity, potentiating the neurotoxic effects of lithium.
  2. A pharmacokinetic interaction where hydrochlorothiazide inhibits the hepatic metabolism of lithium, thereby decreasing its clearance.
  3. A pharmacokinetic interaction where hydrochlorothiazide displaces lithium from its plasma protein binding sites, increasing the free fraction.
  4. A pharmacokinetic interaction where hydrochlorothiazide-induced sodium depletion leads to increased proximal tubular reabsorption of lithium. (correct answer)
Explanation: The correct answer describes the primary pharmacokinetic interaction between thiazide diuretics and lithium. Thiazides inhibit sodium reabsorption in the distal convoluted tubule, leading to increased sodium excretion (natriuresis). The body compensates for this sodium loss by increasing the reabsorption of sodium in the proximal tubule. Because lithium ions are handled similarly to sodium ions in the proximal tubule, their reabsorption is also increased, leading to decreased renal clearance of lithium and a subsequent rise in serum levels to toxic concentrations. A is incorrect because the mechanism is pharmacokinetic (related to excretion), not pharmacodynamic. B is incorrect because lithium is a simple ion and is not metabolized by the liver; it is cleared almost exclusively by the kidneys. C is incorrect because lithium is not significantly bound to plasma proteins.

Question 15

A patient taking fluoxetine for major depressive disorder requires analgesia after a dental procedure and is prescribed a combination product containing codeine. The patient reports minimal pain relief despite taking the medication as directed.

The lack of analgesic efficacy is most likely due to which type of drug interaction?

  1. A pharmacodynamic interaction where fluoxetine antagonizes mu-opioid receptors in the central nervous system, blocking the effects of codeine.
  2. A pharmacokinetic interaction where fluoxetine induces the rapid metabolism of codeine into inactive metabolites, reducing its effective half-life.
  3. A pharmacodynamic interaction where elevated serotonin levels from fluoxetine alter pain perception pathways, rendering opioid analgesics ineffective.
  4. A pharmacokinetic interaction where fluoxetine, a potent CYP2D6 inhibitor, prevents the metabolic conversion of codeine to its active metabolite, morphine. (correct answer)
Explanation: The correct answer describes the pharmacokinetic basis for this interaction. Codeine is a prodrug that exerts most of its analgesic effect after being metabolized into morphine. This conversion is primarily carried out by the CYP2D6 enzyme. Fluoxetine (and its active metabolite, norfluoxetine) is a potent inhibitor of CYP2D6. By inhibiting the enzyme, fluoxetine blocks the activation of codeine, leading to low morphine levels and a lack of analgesic effect. A is incorrect; the mechanism is PK, not PD. Fluoxetine does not block opioid receptors. B is incorrect as fluoxetine is an inhibitor, not an inducer, of CYP2D6. C describes a plausible-sounding but incorrect PD mechanism. The primary interaction is the well-documented PK effect on codeine's activation.

Question 16

A patient with a history of both asthma and essential hypertension is brought to the emergency department with acute bronchospasm. They report taking their albuterol inhaler multiple times with little relief. Their medication list is reviewed and found to include propranolol.

The diminished response to albuterol is best explained by:

  1. A pharmacokinetic interaction where propranolol induces the hepatic metabolism of albuterol, lowering its systemic concentration.
  2. A pharmacodynamic interaction due to competitive antagonism, where propranolol blocks beta-2 adrenergic receptors in bronchial smooth muscle. (correct answer)
  3. A physiological antagonism where propranolol's effect on heart rate indirectly reduces drug delivery to the lungs.
  4. A pharmacokinetic interaction where albuterol and propranolol compete for the same plasma protein binding sites, reducing free albuterol.
Explanation: The correct answer describes a classic pharmacodynamic interaction at the receptor level. Albuterol is a beta-2 adrenergic receptor agonist; its binding to these receptors in the lungs causes bronchodilation. Propranolol is a non-selective beta-adrenergic antagonist, meaning it blocks both beta-1 and beta-2 receptors. By blocking the beta-2 receptors in the bronchial smooth muscle, propranolol directly opposes and prevents the therapeutic effect of albuterol. This is a competitive antagonism. A is incorrect as the interaction is pharmacodynamic, not pharmacokinetic. C describes an implausible mechanism; the primary interaction is direct receptor blockade in the target tissue. D describes a pharmacokinetic mechanism that is not clinically significant for this drug pair.

Question 17

A renal transplant recipient is stable on a maintenance dose of tacrolimus, an immunosuppressant. They begin self-medicating with St. John's Wort for mild depression. A routine blood test reveals that their tacrolimus trough levels are dangerously low, placing them at high risk for organ rejection.

The observed change in tacrolimus levels is best explained by:

  1. A pharmacokinetic interaction where St. John's Wort, a potent inducer of CYP3A4 and P-glycoprotein, has increased the clearance of tacrolimus. (correct answer)
  2. A pharmacokinetic interaction where St. John's Wort inhibits CYP3A4 and P-glycoprotein, paradoxically leading to increased clearance.
  3. A pharmacodynamic interaction where St. John's Wort has a pro-inflammatory effect that counteracts the immunosuppressive action of tacrolimus.
  4. A pharmacokinetic interaction where St. John's Wort enhances the glomerular filtration of tacrolimus without affecting its metabolism.
Explanation: The correct answer identifies a well-documented pharmacokinetic interaction. Tacrolimus is a substrate of both the metabolic enzyme CYP3A4 and the efflux transporter P-glycoprotein, both of which are highly expressed in the gut and liver. St. John's Wort is a potent inducer of both CYP3A4 and P-glycoprotein. By inducing these systems, St. John's Wort significantly increases both the first-pass and systemic metabolism and clearance of tacrolimus, leading to subtherapeutic blood levels and the risk of allograft rejection. B incorrectly states that St. John's Wort is an inhibitor. C describes a pharmacodynamic mechanism, but the observed change in drug levels clearly points to a pharmacokinetic interaction. D describes an incorrect pharmacokinetic mechanism; the effect is on metabolism and transport, not glomerular filtration.

Question 18

A patient is at a stable steady state on Drug X, a narrow therapeutic index anticoagulant that is 99% bound to plasma albumin. Therapy is initiated with Drug Y, which is also highly albumin-bound and displaces a small fraction of Drug X from its binding sites.

Which statement most accurately describes the initial pharmacokinetic and clinical consequence for Drug X immediately following administration of Drug Y?

  1. The percentage of free Drug X will transiently increase, potentially leading to an immediate increase in therapeutic or toxic effects. (correct answer)
  2. The total concentration of Drug X will immediately decrease, causing a loss of therapeutic effect due to enhanced competition.
  3. The volume of distribution of Drug X will decrease as it is confined to the plasma, reducing its effect at tissue sites.
  4. The rate of hepatic metabolism and renal excretion of Drug X will immediately decrease because less total drug is available for clearance.
Explanation: The correct answer describes the immediate effect of protein binding displacement. When Drug Y displaces Drug X, the amount of unbound (free) Drug X in the plasma momentarily increases. For a highly bound drug (99%), even a small displacement can double the free concentration (e.g., from 1% to 2%). Since the free drug is the pharmacologically active portion, this can lead to an acute increase in the drug's effect, potentially causing toxicity. This effect is transient because the increased free fraction is now available for metabolism and excretion, which will eventually lead to a new steady state with a lower total drug concentration but a similar free drug concentration. However, the initial spike is the period of greatest clinical risk. B is incorrect; total concentration decreases over time, not immediately. C is incorrect; displacement from plasma proteins increases the apparent volume of distribution as more drug can move into the tissues. D is incorrect; clearance mechanisms act on the free drug, so an increase in free fraction will initially increase the rate of clearance.

Question 19

A patient receiving high-dose methotrexate for osteosarcoma develops severe myelosuppression and mucositis. A review of their medications reveals they have also been taking another prescription drug concurrently.

Which of the following co-administered drugs and mechanisms would most likely explain the development of methotrexate toxicity?

  1. Probenecid, via a pharmacokinetic interaction that inhibits the organic anion transporters (OATs) in the renal tubules, decreasing methotrexate excretion. (correct answer)
  2. Leucovorin, via a pharmacodynamic interaction that competitively binds to dihydrofolate reductase, thereby potentiating methotrexate's effect.
  3. Omeprazole, via a pharmacokinetic interaction that induces the CYP enzymes responsible for methotrexate metabolism, creating toxic metabolites.
  4. Penicillin, via a pharmacokinetic interaction where it displaces methotrexate from plasma protein binding sites, increasing its total concentration.
Explanation: The correct answer identifies a significant pharmacokinetic interaction affecting excretion. Methotrexate is primarily cleared from the body by active secretion into the renal tubules via transporters like OATs. Probenecid is a potent inhibitor of these transporters. By blocking OATs, probenecid can markedly decrease the renal clearance of methotrexate, leading to a prolonged half-life and accumulation to toxic levels. B is incorrect. Leucovorin (folinic acid) is used as a rescue agent to reduce methotrexate toxicity by bypassing the DHFR enzyme block; it does not potentiate the effect. C is incorrect. Methotrexate is not significantly metabolized by CYP enzymes. Some proton pump inhibitors can interfere with methotrexate clearance, but the mechanism is inhibition of renal transporters, not CYP induction. D is incorrect because while penicillins can also inhibit renal secretion of methotrexate, the primary effect of displacement from protein binding is a transient increase in the free fraction, not total concentration, and the major interaction is at the level of renal excretion.

Question 20

A patient who chronically consumes large amounts of alcohol is given a standard intravenous dose of diazepam for procedural sedation. The patient experiences profound and prolonged respiratory depression, far greater than anticipated.

Which combination of interactions best explains this exaggerated response?

  1. Pharmacodynamic antagonism at the GABA-A receptor, combined with pharmacokinetic induction of diazepam metabolism from chronic alcohol use.
  2. A purely pharmacokinetic interaction where acute alcohol intake blocks the renal excretion of diazepam and its active metabolites.
  3. Pharmacodynamic synergism at the GABA-A receptor, combined with a pharmacokinetic interaction where acute alcohol intake inhibits diazepam metabolism. (correct answer)
  4. A purely pharmacodynamic interaction where both agents non-competitively inhibit CNS neurotransmission through separate, unrelated pathways.
Explanation: The correct answer acknowledges both a key pharmacodynamic and a key pharmacokinetic interaction. Pharmacodynamically, both ethanol and benzodiazepines like diazepam are positive allosteric modulators of the GABA-A receptor, the primary inhibitory neurotransmitter receptor in the CNS. Their combined action leads to synergistic CNS depression. Pharmacokinetically, while chronic alcohol use induces CYP enzymes, acute high-dose alcohol consumption can competitively inhibit CYP enzymes (like CYP3A4 and 2C19) that metabolize diazepam, slowing its clearance and prolonging its effects. The combination of these two mechanisms explains the profound sedation. A is incorrect; the interaction is synergistic, not antagonistic, and while chronic induction is a factor, acute inhibition is more relevant to this scenario. B is incorrect; diazepam is cleared by hepatic metabolism, not primarily renal excretion. D is incorrect because the interaction is not purely pharmacodynamic, and the agents act on the same receptor complex, not unrelated pathways.